within Pharmacolibrary.Drugs.N_NervousSystem.N03A_Antiepileptics.N03AG05_Progabide;

model Progabide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 4.8611111111111115e-05,
    adminDuration = 600,
    adminMass = 1200 / 1000000,
    adminCount = 1,
    Vd = 0.0012,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Progabide</td></tr><tr><td>ATC code:</td><td>N03AG05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>1200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.5</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Progabide is a gamma-aminobutyric acid (GABA) agonist anticonvulsant drug previously used in the treatment of epilepsy. It acts as a GABA receptor agonist to enhance inhibitory neurotransmission. Its use is discontinued or very limited today, and it is not approved in most countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult population; no detailed human PK studies published in English literature, values are based on secondary pharmacology sources and estimation.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N03AG05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Progabide;
